Efbemalenograstim alfa

Therapeutic indications

Efbemalenograstim alfa is indicated for:

Neutropenia due to cytotoxic chemotherapy for malignancy

Population group: only adults (18 years old or older)

Efbemalenograstim alfa is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Efbemalenograstim alfa is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Myelodysplastic syndrome, chronic myelogenous leukaemia, acute myeloid leukaemia

at least one of
Myelodysplastic syndrome (clinical)
Chronic myeloid leukemia
Acute myeloid leukemia

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2023: RYZNEUTA Solution for injection
Summary of Product Characteristics (SPC) 2024: RYZNEUTA Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈